Chugai Pharmaceutical Co., Ltd.
$3.2M 133 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
BioLineRx USA, Inc.
BioLineRx USA, Inc. reported $3,252,822.72 across General Payments, Research, and Ownership to 137 physicians and teaching hospitals across 169 transactions.
- $3.3M Top quartile payer
- All-tracks total
- 169 Above-median volume
- Transactions
- 137 Above-median reach
- Recipients
- #344
- of 1,925 companies
BioLineRx USA, Inc. reported $3,252,822.72 across all CMS Open Payments tracks (General + Research + Ownership) to 137 physicians and teaching hospitals in Program Year 2024 - ranking #344 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $112,250.24, averaging $23.7K per recipient.
How BioLineRx USA, Inc.'s $3.3M all-tracks total breaks down
BioLineRx USA, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
31/100
Total payments
F
40/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer biolinerx-usa-inc BioLineRx USA, Inc.
$3.3M · #344/1,925 · 0.0% industry · PY2024
- TOT $3.3M
- RANK #344
- SHARE 0.0%
- TXN 169
- RCP 137
- CAT 5
- GEN $112.3K
- TOP1 17.4%
- PY 2024
Volume peers
Nearest volume peer: Chugai Pharmaceutical Co., Ltd. ($3.2M)
BioLineRx USA, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for BioLineRx USA, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For BioLineRx USA, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 5-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $61.4K, accounting for 54.7% of this company's General Payments and 29 transactions.
General Payment Breakdown by Type
Across 5 types of general payments, BioLineRx USA, Inc.'s largest category was "Consulting Fee" at $61.4K - 54.7% of General Payments.
BioLineRx USA, Inc. reports 5 general-payment categories - the top three are Consulting Fee (54.7%), Compensation for Faculty or Speaker (Medical Education) (18.5%), and Grant (18.3%). The remaining 2 categories make up 8.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How BioLineRx USA, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $61.4K | 29 | 54.7% |
| Compensation for Faculty or Speaker (Medical Education) | $20.8K | 8 | 18.5% |
| Grant | $20.5K | 3 | 18.3% |
| Food and Beverage | $6.6K | 90 | 5.8% |
| Travel and Lodging | $3.0K | 7 | 2.7% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $51,500.47 (45.9%) of $112,250.24 in this company's General Payments records across 88 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for BioLineRx USA, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Henry Fung
$19,479.96 across 10 reported transactions
- 2
Zachary D Crees
$9,000.00 across 3 reported transactions
- 3
Karmanos Cancer Hospital
$8,000.00 across 1 reported transactions
- 4
Stephan Grupp
$7,520.51 across 4 reported transactions
- 5
Scripps Memorial Hospital-Encinitas
$7,500.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
BioLineRx USA, Inc. ranks #344 of 1,925 by total payments (top 18% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,196 of 1,838 by HHI (bottom 35% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Acella Pharmaceuticals, LLC : $103.8K total payments, HHI 660
- Ortho Solutions Inc : $57.2K total payments, HHI 656
- Endomagnetics Ltd : $228.3K total payments, HHI 655
- Medartis Inc. : $1.0M total payments, HHI 655
- KARL STORZ Endoscopy-America : $1.4M total payments, HHI 655
- Advanced Critical Devices, Inc. : $1.2K total payments, HHI 653
- BioLineRx USA, Inc. (this company) : $112.3K total payments, HHI 652
- Cardinal Health 108 LLC : $1.8K total payments, HHI 651
- ADMA BioManufacturing LLC : $167.7K total payments, HHI 650
- Expanding Innovations, Inc. : $130.8K total payments, HHI 649
- US Implant Solutions, LLC : $157.1K total payments, HHI 646
- Edap Technomed Inc : $640.3K total payments, HHI 644
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as BioLineRx USA, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about BioLineRx USA, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with BioLineRx USA, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Endo USA, Inc.
$3.2M 10,750 recipients
Compare payment profiles
BeiGene AUS Pty Ltd
$3.2M 0 recipients
Compare payment profiles
Kowa Holdings America, Inc.
$3.3M 0 recipients
Compare payment profiles
Phasor Health, LLC
$3.2M 0 recipients
Compare payment profiles
Viseon, Inc.
$3.2M 67 recipients
Compare payment profiles
Put this to use
BioLineRx USA, Inc. ranks #344 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where BioLineRx USA, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just BioLineRx USA, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.